본문 바로가기
  • Home

Review on the Study of Sibjeondaebo-tang (Shiquan dabutang) Published in Korea from 2000 to 2013

  • Journal of Korean Medicine Rehabilitation
  • Abbr : JKMR
  • 2014, 24(1), pp.47-53
  • Publisher : The Korean Academy Of Oriental Rehabilitation Medicine
  • Research Area : Medicine and Pharmacy > Korean Medicine

정훈 1 So-Jung Park 2 이형은 1 김빛나라 1 LEE EUN JUNG 2 Minseok Oh 2 Dongseok Heo 2

1대전대학교 한의과대학 한방재활의학과교실
2대전대학교

Accredited

ABSTRACT

Objectives The aim of this review is to analyse the study tendency in papers related with sibjeondaebotang (Shiquan dabutang) which are published in Korea from 2000 to 2013. Methods We searched the four electronic database (NSDL, RISS, Korean traditional knowledge portal, OASIS) and checked relevant Korean journals from 2000 to 2013. We classified the papers by publish date, speciality, study method, and field of study, and analysed the study tendency. Results 1. 4 papers were published annually on average. 2. After classifying papers by the speciality of journal, continuous study was followed not only in korean medicine, but also in many specialities like Dietetics, Biotechnology and Pharmacology. 3. In study methods, clinical case was 29%, in vivo was 26%, and in vitro was 26%. 4. After classifying papers by field of study, beneficial effect was 62%, toxicity was 14%, qualitative analysis was 9%, and adverse effect and pharmacology was 3%. 5. In beneficial effect, it is effective in antioxidation, treatment and prevention of neurologic disease, skin disease, gynecologic disease and so on. It has also an effect in enhancing the immune system, improving the dysfunction of organs, and it can also be used for anticancer and anti-metastatic purpose. Conclusions These results suggest that Sibjeondaebotang (Shiquan dabutang) can be used as cure medicine, not just as herbal tonic, but there are not sufficient evidence based papers, so there should be further studies in order to establish Sibjeondaebotang as a cure medicine.

Citation status

* References for papers published after 2023 are currently being built.